[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - Elsevier
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto… - Lung Cancer …, 2013 - europepmc.org
Methods Eligible patients received erlotinib 150 mg/day until disease progression or
unacceptable toxicity. The primary endpoints were progression-free survival (PFS) and …
unacceptable toxicity. The primary endpoints were progression-free survival (PFS) and …
[PDF][PDF] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori… - Lung …, 2013 - cyberleninka.org
abstract Introduction: The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor
erlotinib is associated with survival benefits in patients with EGFR mutation-positive non …
erlotinib is associated with survival benefits in patients with EGFR mutation-positive non …
[PDF][PDF] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - core.ac.uk
abstract Introduction: The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor
erlotinib is associated with survival benefits in patients with EGFR mutation-positive non …
erlotinib is associated with survival benefits in patients with EGFR mutation-positive non …
[HTML][HTML] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori… - Lung …, 2013 - lungcancerjournal.info
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
[引用][C] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K GOTO, M NISHIO, T FUKUYAMA, T TAMURA… - Lung …, 2013 - pascal-francis.inist.fr
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese
patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell …
patients with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell …
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto… - Lung cancer …, 2013 - pubmed.ncbi.nlm.nih.gov
Introduction The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
is associated with survival benefits in patients with EGFR mutation-positive non-small-cell …
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - infona.pl
The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor erlotinib is associated
with survival benefits in patients with EGFR mutation-positive non-small-cell lung cancer …
with survival benefits in patients with EGFR mutation-positive non-small-cell lung cancer …
[PDF][PDF] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori… - Lung …, 2013 - researchgate.net
abstract Introduction: The epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitor
erlotinib is associated with survival benefits in patients with EGFR mutation-positive non …
erlotinib is associated with survival benefits in patients with EGFR mutation-positive non …
[引用][C] A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients with epidermal growth factor receptor (EGFR) mutation-positive …
K Goto, M Nishio, N Yamamoto, K Chikamori, T Hida… - Lung Cancer, 2013 - cir.nii.ac.jp
A prospective, phase II, open-label study (JO22903) of first-line erlotinib in Japanese patients
with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung …
with epidermal growth factor receptor (EGFR) mutation-positive advanced non-small-cell lung …